Predict your next investment

HEALTHCARE | Drug Development
xo1.co.uk

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$11M

About XO1

XO1 is a biotechnology company formed specifically to develop ichorcumab. It is a virtual company, with no offices or laboratory space, and operates by engaging high quality contract research and development specialists in Europe and the US, managed by a small team of experienced drug developers. Properly managed, virtual drug development not only controls costs but maximizes quality through the flexible selection of the most appropriate supplier for each individual task.

XO1 Headquarter Location

25 Fiddle Bridge Lane Hatfield

Hertfordshire, England, AL10 0SP,

United Kingdom

Latest XO1 News

NASA Identifies Near-Collision Asteroid to Fly Past Earth on Friday the 13th

Dec 12, 2019

NASA Identifies Near-Collision Asteroid to Fly Past Earth on Friday the 13th https://sputniknews.com/europe/201912121077547160-nasa-identifies-near-collision-asteroid-to-fly-past-earth-on-friday-the-13th/ NASA has been monitoring an asteroid which maintains an orbit around various bodies in the solar system and consistently passes through Earth's orbit with the sun. 13 near-Earth objects in total are expected to fly past Earth in December of this year. Earth is set to have a close encounter with an  enormous asteroid which is set to fly nearby Earth on Friday at a speed of almost 18,000 miles an hour (more than 28,000 km/h), according to NASA. The upcoming pass-by is estimated to happen on 8:25 am on 13 December, the unlucky Friday the 13th. The asteroid’s orbit diagram indicates that the near-Earth approach will follow the rock's intersection with Earth's orbit. According to the space agency's Center for Near-Earth Object Studies (CNEOS) , the asteroid has an Earth-crossing orbit with the sun and will not approach from a diagonal or perpendicular direction and instead will flyby perpendicular to earth. It is expected to pass by earth at a shockingly close 0.03033 astronomical units, around 1.9 million miles (more than 3mn km) away. NASA has dubbed the asteroid 2019 XO1 and estimate that it is around 243-feet wide, about the width of a Boeing 747 plane. According to CNEOS, 2019 XO1 is classified as an Aten asteroid , meaning that its orbit circulates around a number of celestial bodies in the solar system including the Sun, Venus, Mercury, and Earth. The asteroid has a tendency to intersect its orbit with Earth's, typically when it is furthest away from the sun. 3 December marked the first time 2019 XO1 was identified in its frequent encroachment on Earth. It also comes close to Mercury and Venus but, unlike its proximity with Earth, it does not cross the paths of the two other planets. The body first came near Earth on 17 November 2013, missing the planet by 0.09488 astronomical units, around 8.8 million miles. Following its passing on Friday the 13th, the asteroid will not come back from Earth's outcrop of the solar system until December 22, 2022, where it will creep as close as 0.09534 astronomical units, up to 8.9 million miles (more than 14Mn km) away. ...

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing XO1

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

XO1 is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.